Cyclica (acquired by Recursion, Nasdaq: RXRX)

Cyclica has officially been acquired by Recursion! If you’ve been following us and believe in our mission, follow Recursion's accounts below to join us as we industrialize #drugdiscovery as one team. ✅ Follow Recursion on LinkedIn ✅ Follow on Twitter @RecursionPharma - https://bit.ly/436tpNn ✅ Subscribe to the @RecursionPharma YouTube channel - https://bit.ly/3C22CWL Help spread the word and share this post with your followers/networks! #techbio #SocialMedia #SocialChannels #biotech #pharma

Last night, on behalf of Recursion (Canada), I hosted a highly enjoyable, engaging, and insightful dinner with many of the healthcare, life sciences and biotech community players in Ontario and Canada, and introduced them to Chris Gibson, Co-founder & CEO of Recursion, and Daniel Cohen, President of Valence Labs (a Recursion company). I was energized that across two tables, people spoke passionately about one topic: How Canada can capture the value that it creates in healthcare innovation The conversations were not filled with pontification and complaints. Instead, what I heard was a common understanding and acceptance of challenges of building, told through real life examples and cases, with a focus on unified solutions that we could all get behind to create our desired future so we can achieve our patient-driven goals faster For us to remain relevant, I heard people say: -We need to double or triple down on our strengths: one of the key strengths of operating a company in Canada is the support system to help companies start and launch. This is through technology evaluation, scientific validation, IP strategy, and trusty-ol SR&ED tax credits - We need to create more bold tax incentives to motivate early stage companies to build and invest here - We need a mindset shift. We need to accept that we aren’t where we want or expect to be. While there’s a lot of momentum in the system and we’ve made a lot of progress over the past 7-10 years, Canada (and Ontario specifically) still punches well below its weight in healthcare innovation - We need more bold and visionary entrepreneurs, founding teams AND investors and financial partners that are committed to building anchor companies that converge cutting-edge technology to drive a paradigm shift - not just incremental change. We need more AbCellera, Xenon Pharmaceuticals Inc., Zymeworks Inc., BenchSci, Gandeeva Therapeutics, Aspect Biosystems, Deep Genomics, and dare I say Cyclica and Valence Labs. Not just 5 - 10 more, but 5 -10 (times) more Building anchor companies takes time and patience. We need to celebrate the micro successes along the journey and recycle the founding teams to go tackle bigger problems here in Canada - We need more coordination and deeply rooted collaboration between and amongst the “ecosystem players” to offer an easy-to-navigate set of programmatic activities and general support. I invite my colleagues, including those from last night, to weigh in, add clarity, or adjust my statements above Parimal Nathwani Dr. Christine Allen Fanny Sie Rebecca Yu Maura Campbell Jason Field Gordon McCauley (He/Him) Amol Deshpande Aled Edwards Roxana Sultan Jim Wilson Karen McClure Derek Newton MaRS Discovery District TIAP - Toronto Innovation Acceleration Partners Ontario Bioscience Innovation Organization (OBIO) Life Sciences Ontario Digital Supercluster University of Toronto adMare BioInnovations McKesson Canada #innovation #entrepreneurship #ecosystem #healthcare #Canada

Today, 11 years after graduating from the University of Toronto - Rotman School of Management, I am humbled and grateful to announce that I’m the recipient of the 2023 Rotman Leader to Watch award. To date, arguably the most unexpected thing that has happened to me (at least the one I remember the most) is being accepted to the Rotman School of Management full-time MBA program. I remember completing the application with my mediocre grades and an uninspiring GMAT score pressing submit and expecting a one-liner that read “you don’t meet our qualifications”. Then, I was invited for an interview. On my way out of the room, feeling super nervous and unsure of how it went, I ran head first into a filing cabinet. Bang! I left 100% expecting a one-liner that read “you don’t meet our qualifications and you should be more careful in life”. Then - against all odds - I was accepted. And my life thereafter changed. More than anything, Rotman inspired me to push for what I believe in and to go big. It did this not just by providing a great education and the fundamental tools to understand and practice business effectively, which it did, but by bringing together a cohort of incredibly talented, diverse, and super smart people, so many of whom I observed were going big in life. My classmates inspired and motivated me. My professors molded and directed me. Together, Rotman unlocked this deeply rooted desire to do something meaningful and enduring in life. It also introduced me to Cyclica which I first heard presented at a Rotman Entrepreneurial & Venture Capital Association (REVCA) case competition. And it’s where I met some of my closest friends who have provided me with unyielding support and guidance over the years. Over the past 10 years, I’ve had the distinct privilege of working with and leading an incredibly talented and dedicated team that built Cyclica, a company that is considered one of the pioneers of what is now the increasingly hot space of AI for Drug Discovery and Development. I am so grateful to my team, without whom nothing would have been possible (most of whom are in the picture here... though there are so many great people over the years that are not included in the pic) In May 2023, Recursion (NASDAQ: RXRX) acquired Cyclica. 🚀 At Recursion, I help lead the Canadian operations as President of Recursion Canada. In this role, I work closely with the Recursion leadership team to help build Recursion into what I believe will a "category-winner" TechBio company, by harnessing the center of gravity in Canada for the best and brightest in ML and AI scientists who want to reimagine how drugs are discovered. Congrats to Rachel Megitt (she / her), Vice President, Term Investments & Savings, RBC InvestEase and Head, RBC Healthcare from receiving the Rotman Volunteer Excellence Award and Victor Dodig, President and CEO, CIBC for receiving the Rotman Lifetime Achievement Award #innovation #entrepreneurship #drugdiscovery #techbio

🎙️This week on the podcast, we revisit a conversation with Naheed Kurji, a Health Transformer who piloted Cyclica until it was acquired by Recursion Pharmaceuticals this year. Now, Kurji finds himself at the leading edge of the next phase of AI drug discovery. https://ow.ly/nZmM50PI0O1

🎙️This week on the podcast, we revisit a conversation with Naheed Kurji, a Health Transformer who piloted Cyclica until it was acquired by Recursion Pharmaceuticals this year. Now, Kurji finds himself at the leading edge of the next phase of AI drug discovery. https://ow.ly/nZmM50PI0O1

Our map-based approach is designed to set the standard for #drugdiscovery in the 21st century. 🎬 In this video, Senior VP of #AI & Digital Sciences Imran Haque shares how we use our Mapping & Navigating Technology to explore both known and unknown areas of disease biology to discover potential new medicines. Watch ⬇️ https://lnkd.in/gjWvVmYB #techbio #machinelearning #ai #artificialintelligence